Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Theravance Biopharma, Inc.
Bear Case (25th pct.)
-32.9% vs price
Base Case (Median)
32.1% vs price
Bull Case (75th pct.)
33.2% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $2.78 | -83.7% | High (40%) |
| PE Comparable | $22.67 | 33.2% | Medium (25%) |
| Graham Number | $11.42 | -32.9% | Medium (40%) |
| EV/EBITDA | $28.98 | 70.3% | Medium (20%) |
| EV/FCF | $22.48 | 32.1% | Medium (20%) |
Based on 5 out of 7 methods, TBPH appears fairly valued at the current price of $17.02. The base case fair value of $22.48 implies 32.1% upside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.